Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of Cagrilintide in Subjects with Renal Impairment
NCT04209049Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Jan 2020
- Primary completion
- Jan 2021
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of cagrilintide in obesity (4 arms), sponsored by Novo Nordisk. Primary endpoint: Area under the plasma NNC0174-0833 concentration-time curve. Started Jan 2020; status: completed.
02
Drugs
cagrilintide
03
Conditions
obesity
Beyond the preview
Go deeper on NCT04209049.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04209049.